Merck & Co., Inc. (NYSE:MRK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Merck & Co. has a consensus analyst rating of “Moderate Buy”, based on 20 covering firms, with an average 1-year price target of about $128.72. Several recent analysts also raised targets or upgraded the stock, reflecting continued Wall Street support.
• The company received important label-expansion approvals for Keytruda-based treatments, including FDA approval for use with Trodelvy in first-line PD-L1+ advanced triple-negative breast cancer and EU approval for Keytruda plus Padcev in certain bladder cancer patients. These approvals could help strengthen Merck’s revenue growth outlook.
• Merck reported quarterly results that beat earnings and revenue estimates, with EPS of -$1.28 versus expectations of -$1.47 and revenue of $16.29 billion versus $15.85 billion expected. The company also boosted its FY 2026 guidance and recently announced a $0.85 quarterly dividend, implying a 2.6% yield.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the twenty ratings firms that are presently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $128.7222.

MRK has been the topic of several recent analyst reports. UBS Group increased their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a research note on Monday, April 13th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a research note on Monday, March 30th. Wall Street Zen raised shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating in a research note on Saturday, June 6th. JPMorgan Chase & Co. raised their price target on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the company an "overweight" rating in a research note on Monday, April 6th. Finally, Citigroup initiated coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a "neutral" rating and a $125.00 price target on the stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced FDA approval for Keytruda and Keytruda Qlex, each combined with Gilead’s Trodelvy, as a first-line treatment for PD-L1+ advanced triple-negative breast cancer, expanding a major revenue-driving franchise. Article Title
• Positive Sentiment: Merck also won EU approval for Keytruda plus Padcev in resectable muscle-invasive bladder cancer patients who cannot receive cisplatin chemotherapy, another label expansion that could support future sales. Article Title
• Positive Sentiment: Merck’s collaboration with Gilead continues to generate attention after positive HIV trial results, helping reinforce confidence in the company’s research pipeline and strategic partnerships. Article Title
• Neutral Sentiment: Merck was highlighted in CNBC’s “Final Trades,” which reflects ongoing market attention but does not by itself change the company’s fundamentals. Article Title
• Neutral Sentiment: Zacks noted that MRK is a trending stock, suggesting elevated investor interest rather than a specific new operating development. Article Title

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of MRK. Chesapeake Wealth Management lifted its stake in Merck & Co., Inc. by 0.6% in the 4th quarter. Chesapeake Wealth Management now owns 14,740 shares of the company's stock worth $1,552,000 after purchasing an additional 87 shares in the last quarter. South Plains Financial Inc. lifted its stake in Merck & Co., Inc. by 0.6% in the 4th quarter. South Plains Financial Inc. now owns 15,535 shares of the company's stock worth $1,635,000 after purchasing an additional 89 shares in the last quarter. Syverson Strege & Co lifted its stake in Merck & Co., Inc. by 2.2% in the 4th quarter. Syverson Strege & Co now owns 4,142 shares of the company's stock worth $436,000 after purchasing an additional 90 shares in the last quarter. Nations Financial Group Inc. IA ADV lifted its stake in Merck & Co., Inc. by 0.4% in the 1st quarter. Nations Financial Group Inc. IA ADV now owns 23,433 shares of the company's stock worth $2,819,000 after purchasing an additional 91 shares in the last quarter. Finally, Westside Investment Management Inc. lifted its stake in Merck & Co., Inc. by 3.1% in the 4th quarter. Westside Investment Management Inc. now owns 3,142 shares of the company's stock worth $331,000 after purchasing an additional 93 shares in the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Trading Up 2.3%

MRK stock opened at $128.35 on Friday. The company's 50-day simple moving average is $116.08 and its 200-day simple moving average is $114.33. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a 52-week low of $76.66 and a 52-week high of $128.78. The firm has a market cap of $316.99 billion, a P/E ratio of 36.15, a PEG ratio of 2.89 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period in the prior year, the company posted $2.22 EPS. The company's revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities analysts forecast that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be paid a $0.85 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.6%. Merck & Co., Inc.'s dividend payout ratio (DPR) is currently 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.